Αρχική World News Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy

Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy

A multicentre, open-label, single-arm, phase II study, conducted in China explored the efficacy and safety of pyrotinib, an oral, irreversible, pan-ErbB tyrosine kinase inhibitor against HER1, HER2, and HER4 in patients with advanced non-small cell lung cancer (NSCLC) harbouring HER2 mutations, who had received at least one prior platinum-containing chemotherapy for advanced/metastatic disease. Caicun Zhou of the Shanghai Pulmonary Hospital, Tongji University School of Medicine in Shanghai, China and co-authors reported on 2 July 2020 in the Journal of Clinical Oncology that pyrotinib as a single agent showed a promising antitumour activity and an acceptable safety profile in that setting.

Combination of pyrotinib and capecitabine is approved in China for HER2-positive advanced breast cancer. A previous study demonstrated more favourable antitumour activity of pyrotinib than afatinib or T-DM1 in the patient-derived HER2-mutated lung cancer xenograft model.

Patients with HER2-mutated NSCLC account for 1-4% of patients with lung adenocarcinoma. The authors wrote in the study background that targeted therapies against NSCLC harbouring HER2 mutations remain an unmet need. In this study (NCT02834936), the Chinese investigators explored the efficacy and safety of pyrotinib in patients with advanced NSCLC and HER2 mutations who had received at least one prior platinum-containing chemotherapy for advanced/metastatic disease.

The investigators enrolled in this study the patients with stage IIIB or IV HER2-mutated lung adenocarcinoma who were previously treated with platinum-based chemotherapy. The primary endpoint was objective response rate (ORR) per independent review committee (IRC).

In total, 60 patients received pyrotinib. At baseline, 58 patients (96.7%) had stage IV disease; 25 patients (41.7%) received at least 2 lines of prior chemotherapy. As of data cut-off on 20 June 2019, IRC-assessed ORR was 30.0% (95% confidence interval [CI] 18.8% to 43.2%).

All subgroups of patients with different HER2 mutation types showed a favourable ORR. The ORRs were similar between patients with and without brain metastases (25.0% vs 31.3%).

The median duration of response was 6.9 months (95% CI 4.9 to 11.1 months).

The median progression-free survival was 6.9 months (95% CI 5.5 to 8.3 months) per IRC.

The median overall survival was 14.4 months (95% CI 12.3 to 21.3 months).

Treatment-related adverse events of grade 3 or 4 occurred in 28.3% of patients, with the most common being diarrhoea (20.0%; all grade 3). No treatment-related deaths were reported.

A major limitation of this study is the lack of a control arm and the small sample size of patients with missense point mutation in HER2. Therefore, the authors were unable to adequately compare the clinical benefit of different subtypes in HER2 mutations.

A global, multicentre, randomised phase III trial is planned and will be started soon.

The authors concluded that it is the largest study in HER2-mutated NSCLC. Pyrotinib 400 mg daily could be given to patients with HER2-mutated advanced NSCLC, who had received at least one prior platinum-based chemotherapy. To avoid diarrhoea, the most common adverse event attributable to pyrotinib, the study team recommended prophylactic loperamide. 

The study was supported by Jiangsu Hengrui Medicine Co, Ltd.

Reference

Zhou C, Li X, Wang Q, et al. Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. JCO; Published online 2 July 2020. DOI: https://doi.org/10.1200/JCO.20.00297 

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում

«Քաղցկեղն իմ համայնքում»-ը Cancer.Net Blog շարքից է, որը ցույց է տալիս աշխարհում քաղցկեղի ազդեցությունը և թե ինչպես են մարդիկ աշխատում իրենց տարածաշրջանում քաղցկեղով մարդկանց...

Ovarian cancer screening trial did not save lives

“The effort from the start was to save lives of women with ovarian cancer. To build evidence for a screening programme that the NHS...

Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma

Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after...

Expressive Writing, What is It?

One of psychotherapy’s main beliefs is that putting thoughts and feelings into words may produce mental health benefits. Of course, this also applies to cancer...

Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer

May 12, 2021, by NCI Staff In triple-negative breast cancer (TNBC), tumor cells don't have estrogen receptors (ER), progesterone receptors (PR), or large amounts of...

‘Will cancer make me infertile?’ – That Cancer Conversation

For the first episode of That Cancer Conversation, we explore infertility and cancer. From teenage body worries to an intercontinental surrogacy story, we chat to...